GB2579149B - Pharmaceutical composition for preventing or treating cancer containing receptor tyrosine kinase inhibitor as active ingredient - Google Patents

Pharmaceutical composition for preventing or treating cancer containing receptor tyrosine kinase inhibitor as active ingredient Download PDF

Info

Publication number
GB2579149B
GB2579149B GB2001368.6A GB202001368A GB2579149B GB 2579149 B GB2579149 B GB 2579149B GB 202001368 A GB202001368 A GB 202001368A GB 2579149 B GB2579149 B GB 2579149B
Authority
GB
United Kingdom
Prior art keywords
preventing
pharmaceutical composition
active ingredient
tyrosine kinase
kinase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2001368.6A
Other versions
GB202001368D0 (en
GB2579149A (en
Inventor
Yeon Ann Ji
Young Song Jie
Choi Hyun-Kyoung
Ni Ryu Hwa
Gu Hwang Sang
Nam Ky-Youb
Jung In-Sung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Inst Radiological & Medical Sciences
Korea Institute of Radiological and Medical Sciences
Original Assignee
Korea Inst Radiological & Medical Sciences
Korea Institute of Radiological and Medical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Inst Radiological & Medical Sciences, Korea Institute of Radiological and Medical Sciences filed Critical Korea Inst Radiological & Medical Sciences
Publication of GB202001368D0 publication Critical patent/GB202001368D0/en
Publication of GB2579149A publication Critical patent/GB2579149A/en
Application granted granted Critical
Publication of GB2579149B publication Critical patent/GB2579149B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
GB2001368.6A 2017-08-03 2018-02-28 Pharmaceutical composition for preventing or treating cancer containing receptor tyrosine kinase inhibitor as active ingredient Active GB2579149B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170098524A KR101948555B1 (en) 2017-08-03 2017-08-03 Pharmaceutical composition for preventing or treating cancer comprising receptor tyrosine kinases inhibitor
PCT/KR2018/002500 WO2019027117A1 (en) 2017-08-03 2018-02-28 Pharmaceutical composition for preventing or treating cancer containing receptor tyrosine kinase inhibitor as active ingredient

Publications (3)

Publication Number Publication Date
GB202001368D0 GB202001368D0 (en) 2020-03-18
GB2579149A GB2579149A (en) 2020-06-10
GB2579149B true GB2579149B (en) 2022-05-11

Family

ID=65233921

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2001368.6A Active GB2579149B (en) 2017-08-03 2018-02-28 Pharmaceutical composition for preventing or treating cancer containing receptor tyrosine kinase inhibitor as active ingredient

Country Status (4)

Country Link
KR (1) KR101948555B1 (en)
DE (1) DE112018003936T5 (en)
GB (1) GB2579149B (en)
WO (1) WO2019027117A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114533885B (en) * 2022-03-25 2023-08-01 南京中医药大学 Compound pharmaceutical composition with isoliensinine and chemotherapeutic drugs as active ingredients

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032882A2 (en) * 2002-10-10 2004-04-22 Smithkline Beecham Corporation Chemical compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008505916A (en) 2004-07-09 2008-02-28 メタバシス・セラピューティクス・インコーポレイテッド Oxygen / nitrogen heterocycle inhibitors of tyrosine phosphatase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032882A2 (en) * 2002-10-10 2004-04-22 Smithkline Beecham Corporation Chemical compounds

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HARRIS, P. A. et al., "Discovery and Evaluation of 2-anilino-5-aryloxazoles as a Novel Class of VEGFR2 Kinase Inhibitors", Journal of Medicinal Chemistry, (20050000), vol. 48, pages 1610 - 1619, See abstract; compound 39; and tables 3-7. * *
LINTNEROVA, L. et al., "A Development of Chimeric VEGFR2 TK Inhibitor Based on Two Ligand Conformers fromPDB: 1Y6A Complex-Medicinal Chemistry Consequences of a TKs Analysis", European Journal of Medicinal Chemistry, (20140000), vol. 72, pages 146 - 159, See abstract; and figure 1 *
MURAR, M. et al., "Novel CLK1 Inhibitors Based on N-aryloxazol-2-amine Skeleton - A Possible Way to Dual VEGFR2 TK/CLK Ligands", European Journal of Medicinal Chemistry, (20161118), vol. 126, pages 754 - 761, * See page 756; and formulas 1-4. * *
RAGNO, R. et al., "Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors: Development and Validation of Predictive 3-D QSAR Models through Extensive Ligand- and Structure-based Approaches", Journal of Computer-Aided Molecular Design, 2015, vol. 29, pp 757 - 776, See pp 757,758;& table 2 *
SHARMA, B. K. et al., "Modeling of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Kinase Inhibitory Activity of 2-anilino-5-aryloxazoles Using Chemometric Tools", Journal of Enzyme Inhibition and Medicinal Chemistry, (2009), vol. 24, no. 1, pages 86-93, See abstract; fig 1; & table I *
VOJTICKOVA, M. et al., "Ynamide Click Chemistry in Development of Triazole VEGFR2 TK Modulators", European Journal of Medicinal Chemistry, (2015), vol. 103, pages 105 - 122, See abstract; and figures 1, 7. *

Also Published As

Publication number Publication date
KR20190014715A (en) 2019-02-13
WO2019027117A1 (en) 2019-02-07
GB202001368D0 (en) 2020-03-18
DE112018003936T5 (en) 2020-04-30
GB2579149A (en) 2020-06-10
KR101948555B1 (en) 2019-02-15

Similar Documents

Publication Publication Date Title
IL254736B (en) Derivative compounds of imidazol[1,2-c]pyrimidine, lsd1 inhibitors, pharmaceutical composition comprising them and use for treating cancer
IL253995A0 (en) Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
MX2020012165A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer.
EP3293177A4 (en) Tyrosine kinase inhibitor and pharmaceutical composition comprising same
IL282801A (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
ZA201908241B (en) N2,n4-diphenylpyrimidine-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer
MY197700A (en) Compounds useful for inhibiting cdk7
CL2014001547A1 (en) Compounds derived from benzothienyl-pyrrolotriazine, such as protein tyrosine kinase inhibitors; preparation process of said compounds; pharmaceutical composition that includes them; and its use for the treatment and / or prevention of cancer and tumor diseases.
SG11202106160WA (en) Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria wikim28 as active ingredient
HK1244704A1 (en) Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
SG11202100076RA (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
HK1258699A1 (en) Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
HK1257615A1 (en) Pharmaceutical composition for treatment of cancer, containing polyphenol compound as active ingredient
ZA201900421B (en) Novel quinazolinone derivatives inhibiting pi3k and pharmaceutical composition containing same
EP3909597A4 (en) Pharmaceutical composition for preventing or treating cancer, containing oligopeptide as active ingredient
IL267829B (en) Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
PH12016501733A1 (en) Pharmaceutical composition for preventing or treating skin rash
MX2017014752A (en) Novel amidoheteroaryl aroyl hydrazide ethynes.
EP3162803A4 (en) New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient
ZA201803320B (en) Pharmaceutical compositions for treating pain
GB2579480B (en) Composition for preventing or treating cancer containing Triazolopyridine-based derivative as active ingredient
GB2579149B (en) Pharmaceutical composition for preventing or treating cancer containing receptor tyrosine kinase inhibitor as active ingredient
SG11202005983TA (en) Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors
EP3360581A4 (en) Pharmaceutical composition for preventing or treating cancer comprising inhibitor of plrg1 (pleiotropic regulator 1) as active ingredient
EP3542797A4 (en) Pharmaceutical composition for preventing or treating dyrk-related diseases, containing pyridine-based compound as active ingredient

Legal Events

Date Code Title Description
789A Request for publication of translation (sect. 89(a)/1977)

Ref document number: 2019027117

Country of ref document: WO